A number of tumour types are associated with activation of c-KIT through its overexpression or through activating mutations [7,9-11], while in highly metastatic melanomas, breast cancer and thyroid carcinoma the progression into a malignant phenotype correlates mostly with loss of c-KIT expression [12-16]. This evidence concerns the gene KIT and breast cancer.